MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-13-2026
Beyond Air Operating Income 2011-2026 | XAIR
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Beyond Air
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -44.5 M | -63 M | -52.1 M | -40.7 M | -22.2 M | -18.1 M | -3.06 M | 9.94 M | -11.1 M | 2.33 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.94 M | -63 M | -24.3 M |
Quarterly Operating Income Beyond Air
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.6 M | -7.66 M | -7.62 M | - | -11 M | -12.8 M | -13.6 M | - | -17 M | -17.5 M | -15.9 M | - | -14 M | -12.6 M | -11.4 M | - | -7.49 M | -6.2 M | -12.8 M | - | -5.62 M | -5.62 M | -4.97 M | -6.6 M | -4.74 M | -4.74 M | -4.27 M | - | -2.4 M | 2.4 M | -2.41 M | -2.44 M | 2.38 M | -2.06 M | -3.07 M | 3.57 M | - | -167 K | -626 K | -923 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.57 M | -17.5 M | -6.56 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 13.18 | 2.93 % | $ 1.78 B |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 63.36 | -1.31 % | $ 3.46 B |  Britain |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.15 | 1.18 % | $ 61.6 M | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.26 | -0.79 % | $ 51.3 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 188.66 | -0.47 % | $ 13.3 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.61 | -2.87 % | $ 38 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.22 | -0.16 % | $ 121 M |  France |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.1 | -5.77 % | $ 314 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 93.88 | -1.04 % | $ 12.7 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.41 | -2.43 % | $ 6.68 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.13 | -1.16 % | $ 1.29 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 26.16 | -0.87 % | $ 221 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 329.07 | 0.48 % | $ 126 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.84 | -2.16 % | $ 372 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.46 | 2.25 % | $ 1.16 B | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.81 | -0.28 % | $ 387 M | USA |
 |
Varex Imaging Corporation
VREX
|
-27.8 M | $ 12.68 | 1.2 % | $ 525 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.08 | 1.89 % | $ 18.3 M | USA |
 |
Vivos Therapeutics
VVOS
|
-19.9 M | $ 0.88 | 4.9 % | $ 9.04 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 38.03 | -0.81 % | $ 1.18 B | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 54.63 | -2.98 % | $ 1.6 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 85.21 | -0.94 % | $ 2.96 B | USA |
 |
PAVmed
PAVM
|
-21.8 M | $ 8.53 | -5.22 % | $ 5.72 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 84.54 | 0.34 % | $ 49.4 B | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.36 | -2.19 % | $ 497 M | USA |